Sandoz Makes U.S., European Headway With First Tysabri Biosimilar

Sandoz’s biosimilar of Biogen’s blockbuster multiple sclerosis drug Tysabri (natalizumab) has gained new regulatory footholds with both the FDA and the European Medicines Agency (EMA).
Source: Drug Industry Daily